Edwards Lifesciences Corp
NYSE:EW

Watchlist Manager
Edwards Lifesciences Corp Logo
Edwards Lifesciences Corp
NYSE:EW
Watchlist
Price: 74.96 USD 0.2%
Market Cap: 44.2B USD
Have any thoughts about
Edwards Lifesciences Corp?
Write Note

Edwards Lifesciences Corp
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Edwards Lifesciences Corp
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Edwards Lifesciences Corp
NYSE:EW
Revenue
$5.6B
CAGR 3-Years
3%
CAGR 5-Years
6%
CAGR 10-Years
10%
Becton Dickinson and Co
NYSE:BDX
Revenue
$20.2B
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
9%
Boston Scientific Corp
NYSE:BSX
Revenue
$15.9B
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
8%
Stryker Corp
NYSE:SYK
Revenue
$22B
CAGR 3-Years
10%
CAGR 5-Years
9%
CAGR 10-Years
9%
Abbott Laboratories
NYSE:ABT
Revenue
$41.2B
CAGR 3-Years
-1%
CAGR 5-Years
6%
CAGR 10-Years
8%
Intuitive Surgical Inc
NASDAQ:ISRG
Revenue
$7.9B
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
14%
No Stocks Found

Edwards Lifesciences Corp
Revenue Breakdown

Breakdown by Geography
Edwards Lifesciences Corp

Total Revenue: 6B USD
100%
United States: 3.5B USD
58.4%
Europe: 1.3B USD
22.2%
Rest Of World: 709.2m USD
11.8%
Japan: 452.4m USD
7.5%
Show More
Show Less

Breakdown by Segments
Edwards Lifesciences Corp

Total Revenue: 6B USD
100%
Transcatheter Aortic Valve Replacement: 3.9B USD
64.6%
Surgical Structural Heart: 999.3m USD
16.6%
Critical Care: 928.1m USD
15.5%
Transcatheter Mitral And Tricuspid Therapies: 197.6m USD
3.3%
Show More
Show Less

Edwards Lifesciences Corp
Glance View

Market Cap
44.2B USD
Industry
Health Care
Economic Moat
None

Nestled at the intersection of medical innovation and patient care, Edwards Lifesciences Corp. has long been a pioneer in the field of heart disease solutions. Emerging from its origins in the 1950s, the company has consistently focused on advancing heart valve technology, a critical area given the prevalence and severity of cardiovascular diseases. Their journey began with the development of the first artificial heart valve, setting a foundation of innovation that continues to propel the company forward. Today, Edwards is renowned for its leadership in transcatheter aortic valve replacement (TAVR) technology, an area that revolutionizes the treatment of aortic stenosis, a condition that narrows heart valves and impedes blood flow. This shift from open-heart surgeries to less invasive procedures, facilitated by Edwards' products, has marked a significant turning point in patient care, minimizing recovery times and enhancing patient outcomes. Financially, Edwards Lifesciences thrives on a robust business model centered around its technologically advanced heart valve systems and critical care technologies. The company operates through a direct sales force as well as strategic partnerships, ensuring their devices reach hospitals and healthcare providers globally. Their commitment to research and development ensures a steady pipeline of innovative products, which not only differentiates them in the market but also drives their profitability. Revenue streams are primarily fueled by the sales of their TAVR systems, surgical heart valves, and monitoring technologies—each designed to meet the complex and evolving needs of patients with structural heart diseases. By continually investing in cutting-edge technology and expanding their global reach, Edwards Lifesciences not only supports its bottom line but also positions itself as a leader in the transformative field of medical device innovation.

EW Intrinsic Value
55.71 USD
Overvaluation 26%
Intrinsic Value
Price

See Also

What is Edwards Lifesciences Corp's Revenue?
Revenue
5.6B USD

Based on the financial report for Sep 30, 2024, Edwards Lifesciences Corp's Revenue amounts to 5.6B USD.

What is Edwards Lifesciences Corp's Revenue growth rate?
Revenue CAGR 10Y
10%

Over the last year, the Revenue growth was -3%. The average annual Revenue growth rates for Edwards Lifesciences Corp have been 3% over the past three years , 6% over the past five years , and 10% over the past ten years .

Back to Top